Bladder cancer study in Portugal
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at the characteristics and outcomes of people with high-risk non-muscle-invasive bladder cancer in Portugal. It aims to understand the disease better and could help improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with bladder cancer between January 2016 and December 2020.
- Your cancer was at a stage called high-risk non-muscle-invasive bladder cancer (this includes carcinoma in situ, high-grade papillary tumors, or T1 tumors).
- Your cancer had not spread to nearby lymph nodes or other parts of the body (stage N0/M0).
- You had not had your bladder removed before the study began.
- You did not participate in any other clinical trial during the study period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how bladder cancer is treated and what biological markers are present in patients in Russia. If you join, you may help doctors learn more about which treatments work best based on your tumor type.
This study is collecting blood, urine, and tissue samples from people with high-risk non-muscle invasive bladder cancer to help develop better tests for tracking the disease. By participating, you might help improve future monitoring and treatment decisions.
This study looks at tumor and blood samples from people with muscle-invasive bladder cancer to find markers that help predict how the disease will progress. It aims to improve personalized treatment for those with this specific stage of bladder cancer.
This trial is a real-world registry that collects information during follow-up for certain early-stage bladder cancer. It may help doctors understand how urinary test results relate to recurrence and guide monitoring over time.
This study follows people with urothelial cancer and certain rare genital (genitourinary) cancers over time to learn how these diseases progress. It may help researchers understand patterns of symptoms and outcomes, even if it is not a drug trial.
This Phase 2 trial tests TARA-002 given directly into the bladder to treat high-grade non–muscle-invasive bladder cancer with active disease. It may help patients who have not previously responded to, or have not received, BCG treatment in the recent past.
Hear when a new Urinary Bladder Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.